#Coronavirus Disease Research #References (by AMEDEO, Nov. 16 ’24)

1. AYYALA-SOMAYAJULA D, Dodge JL, Leventhal AM, Terrault NA, et al
   Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study.
   Ann Intern Med. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157.
   PubMed        

   Antiviral Res

2. SAMA B, Selisko B, Falcou C, Fattorini V, et al
   The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
   Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
   PubMed         Abstract available

   BMJ

3. GREENHALGH T, Misak C, Payne R, Swann N, et al
   Patient involvement in developing clinical guidelines.
   BMJ. 2024;387:q2433.
   PubMed        

   Br J Anaesth

4. ANGELOPOULOS N, Staines J, Chamberlin M, Bates S, et al
   A narrative review of personal protective equipment gowns: lessons from COVID-19.
   Br J Anaesth. 2024 Nov 7:S0007-0912(24)00567-1. doi: 10.1016/j.bja.2024.
   PubMed         Abstract available

   Clin Infect Dis

5. GRANT R, de Kraker MEA, Buetti N, Jackson H, et al
   In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
   Clin Infect Dis. 2024 Nov 13:ciae558. doi: 10.1093.
   PubMed         Abstract available
6. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
   Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
   Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

7. CREPPAGE KE, Gallaway MS, Russell DA, Early JM, et al
   Global Emerging Infections Surveillance Program Contributions to Pandemic Preparedness and Response.
   Emerg Infect Dis. 2024;30:9-12.
   PubMed         Abstract available
8. MORTON LC, Rahman N, Bishop-Lilly KA
   Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance.
   Emerg Infect Dis. 2024;30:13-18.
   PubMed         Abstract available
9. MUEHLEMAN D, Gruner B, Hogan V, Fanning P, et al
   Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.
   Emerg Infect Dis. 2024;30:53-61.
   PubMed         Abstract available
10. TINOCO YO, Osman TS, Ampuero JS, Gazo M, et al
    Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020-2022.
    Emerg Infect Dis. 2024;30:26-32.
    PubMed         Abstract available
11. ODUNDO EA, Kipkirui EC, Koech MC, Kirui MC, et al
    Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
    Emerg Infect Dis. 2024;30:86-93.
    PubMed         Abstract available

    Int J Infect Dis

12. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed        
13. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to ‘Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study’.
    Int J Infect Dis. 2024;149:107286.
    PubMed        

    Intensive Care Med

14. KESECIOGLU J, Rusinova K, Alampi D, Arabi YM, et al
    European Society of Intensive Care Medicine guidelines on end of life and palliative care in the intensive care unit.
    Intensive Care Med. 2024 Oct 3. doi: 10.1007/s00134-024-07579.
    PubMed         Abstract available
15. OLMOS M, Esperatti M, Fuentes N, Miranda Tirado A, et al
    Early physiologic changes after awake prone positioning predict clinical outcomes in patients with acute hypoxemic respiratory failure.
    Intensive Care Med. 2024 Nov 14. doi: 10.1007/s00134-024-07690.
    PubMed         Abstract available

    J Infect

16. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available
17. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available
18. FOONG KS
    Corrigendum to “The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19” [J Infe
    J Infect. 2024;89:106343.
    PubMed        

    J Med Virol

19. USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    PubMed         Abstract available
20. ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    PubMed         Abstract available
21. ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    PubMed         Abstract available
22. FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    PubMed         Abstract available
23. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed         Abstract available
24. YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    PubMed         Abstract available

    J Virol

25. CHEN Y, Ou X, Li P, Zan F, et al
    Identification of the critical residues of TMPRSS2 for entry and host range of human coronavirus HKU1.
    J Virol. 2024 Nov 11:e0158724. doi: 10.1128/jvi.01587.
    PubMed         Abstract available
26. STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed         Abstract available

    JAMA

27. ANDERER S
    FDA Authorizes First At-Home COVID-19 and Flu Combo Test.
    JAMA. 2024 Nov 8. doi: 10.1001/jama.2024.22561.
    PubMed        

    Lancet

28. DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    PubMed         Abstract available
29. ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    PubMed        
30. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed         Abstract available

    Lancet Infect Dis

31. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed        
32. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed        

    MMWR Morb Mortal Wkly Rep

33. LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
34. MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    N Engl J Med

35. SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed        
36. WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed        
37. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed         Abstract available

    Nature

38. JIAN F, Wang J, Yisimayi A, Song W, et al
    Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Nature. 2024 Nov 7. doi: 10.1038/s41586-024-08315.
    PubMed         Abstract available
39. SOLIMAN A
    US trust in scientists plunged during the pandemic – but it’s starting to recover.
    Nature. 2024 Nov 14. doi: 10.1038/d41586-024-03723.
    PubMed        

    Science

40. CHEN Z, Tsui JL, Gutierrez B, Busch Moreno S, et al
    COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses.
    Science. 2024;386:eadq3003.
    PubMed         Abstract available
41. ROHANI P, Bahl J
    Collateral effects of pandemic control.
    Science. 2024;386:620-621.
    PubMed         Abstract available
42. VOGEL G
    ‘America first’ could affect health worldwide.
    Science. 2024;386:715.
    PubMed         Abstract available

1. SELINGER S
   Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02441.
   PubMed         Abstract available

   BMJ

2. BARRETT A
   Covid-19: Australian inquiry calls for establishment of a national centre for disease control and action to tackle inequities.
   BMJ. 2024;387:q2420.
   PubMed        

   Clin Infect Dis

3. MORTEZAVI M, Sloan A, Singh RSP, Chen LF, et al
   Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
   Clin Infect Dis. 2024 Nov 2:ciae529. doi: 10.1093.
   PubMed         Abstract available

   Int J Infect Dis

4. NAVEED Z, Li J, Wilton J, Naus M, et al
   Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study.
   Int J Infect Dis. 2024 Nov 1:107287. doi: 10.1016/j.ijid.2024.107287.
   PubMed         Abstract available
5. EPSTEIN-SHUMAN A, Hunt JH, Caturegli P, Winguth P, et al
   Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
   Int J Infect Dis. 2024 Nov 1:107289. doi: 10.1016/j.ijid.2024.107289.
   PubMed         Abstract available

   Intensive Care Med

6. WANG Y, Hao S, Song J, Zhong M, et al
   Reflections on awake prone positioning in COVID-19: considerations on body inclination, respiratory support, and patient variability.
   Intensive Care Med. 2024 Nov 4. doi: 10.1007/s00134-024-07710.
   PubMed        

   J Infect

7. WANG H, Zhou Y, Chu L, Chen K, et al
   Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
   J Infect. 2024;89:106333.
   PubMed        
8. HO A, McInnes N, Blunsum A, Quinn J, et al
   Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
   J Infect. 2024;89:106338.
   PubMed         Abstract available

   J Virol

9. CHEN D, Zhang W, Xiao B, Xu B, et al
   Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
   J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
   PubMed         Abstract available
10. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed         Abstract available
11. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed         Abstract available

    Life Sci

12. MARANGI M, Boughattas S, Benslimane F
    Gut microbiome profile to the level species in diarrheic protozoan-carrier patients in Italy.
    Life Sci. 2024 Oct 25:123182. doi: 10.1016/j.lfs.2024.123182.
    PubMed         Abstract available
13. ASHRAF MS, Tuli K, Moiz S, Sharma SK, et al
    AMP kinase: A promising therapeutic drug target for post-COVID-19 complications.
    Life Sci. 2024;359:123202.
    PubMed         Abstract available

    Zhonghua Jie He He Hu Xi Za Zhi

14. LIANG SF, Li WM, Liu D
    [Progress and challenges in clinical diagnosis and treatment of co-existent lung cancer and pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:1035-1041.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/10/coronavirus-disease-research-references-by-amedeo-nov-10-24/

1. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
   Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
   Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
   PubMed         Abstract available

   BMJ

2. DOWNAR J, Close E, Young JE, White BP, et al
   Assisted dying: balancing safety with access.
   BMJ. 2024;387:q2382.
   PubMed        

   Clin Infect Dis

3. BHIMRAJ A, Falck-Ytter Y, Kim AY, Li JZ, et al
   2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.
   Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

4. QADDOURA A, McQuiston M, Tyrrell G, Croxen M, et al
   Analysis of invasive group A streptococcal puerperal sepsis in Calgary, Alberta: clinical consequences and policy implications.
   Infect Control Hosp Epidemiol. 2024;45:1-4.
   PubMed         Abstract available

   J Med Virol

5. SONG K, Hasan A, Hao W, Wu Y, et al
   Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles.
   J Med Virol. 2024;96:e70020.
   PubMed         Abstract available
6. YILDIZ Y, Yasar E, Ozturk E, Karakan MS, et al
   Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.
   J Med Virol. 2024;96:e70030.
   PubMed         Abstract available

   J Virol

7. LIU X, Zhang M, Yin L, Kang L, et al
   PEDV evades MHC-I-related immunity through nsp1-mediated NLRC5 translation inhibition.
   J Virol. 2024 Oct 31:e0142124. doi: 10.1128/jvi.01421.
   PubMed         Abstract available
8. SHI L, Duan Y, Cao L, Zhang Y, et al
   PF-00835231 broadly inhibits swine Alpha-coronavirus, including emerging SADS-CoV.
   J Virol. 2024 Oct 31:e0130324. doi: 10.1128/jvi.01303.
   PubMed         Abstract available
9. HOFFMANN M, Kleine-Weber H, Graichen L, Nehlmeier I, et al
   Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cells.
   J Virol. 2024 Oct 29:e0130524. doi: 10.1128/jvi.01305.
   PubMed         Abstract available

   JAMA

10. TADROUS M, Callaway Kim K, Hernandez I, Rothenberger SD, et al
    Differences in Drug Shortages in the US and Canada.
    JAMA. 2024 Oct 31. doi: 10.1001/jama.2024.17688.
    PubMed         Abstract available

    Lancet Infect Dis

11. PASCAL G
    COVID-19 in South Asia.
    Lancet Infect Dis. 2024 Oct 22:S1473-3099(24)00723.
    PubMed        
12. OKADA Y, Kumagai Y, Okura I, Otsuki M, et al
    Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
    Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565.
    PubMed         Abstract available

    Life Sci

13. YU LC
    Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms.
    Life Sci. 2024;358:123153.
    PubMed         Abstract available
14. WANG N, Fan H, Wang Y, Shu C, et al
    The hybrid immunity defined by weaker immune imprinting of people living with HIV has a stronger neutralizing response against Omicron variants. A suggested explanation for fewer symptoms in people living with HIV after SARS-CoV-2 variants breakthroug
    Life Sci. 2024 Oct 29:123197. doi: 10.1016/j.lfs.2024.123197.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

15. BELL J, Meng L, Barbre K, Wong E, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel – National Healthcare Safety Network, United States, 2023-24 Respiratory Virus Season.
    MMWR Morb Mortal Wkly Rep. 2024;73:966-972.
    PubMed         Abstract available
16. JONES CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, et al
    Routine Vaccination Coverage – Worldwide, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:978-984.
    PubMed         Abstract available

    N Engl J Med

17. LITWINSKA-KMIECIK A, Mrowczynski K
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1658-1659.
    PubMed        
18. YANG C, Tebbutt SJ
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1659.
    PubMed        
19. XIE Y, Al-Aly Z
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras. Reply.
    N Engl J Med. 2024;391:1659-1660.
    PubMed        

    Nature

20. LIU P, Huang ML, Guo H, McCallum M, et al
    Design of customized coronavirus receptors.
    Nature. 2024 Oct 30. doi: 10.1038/s41586-024-08121.
    PubMed         Abstract available

    Science

21. LONG K
    Keeping outbreaks at bayCrisis Averted: The Hidden Science of Fighting Outbreaks Caitlin Rivers Viking, 2024. 320 pp.
    Science. 2024;386:499.
    PubMed         Abstract available
22. KUPFERSCHMIDT K
    You won’t believe this.
    Science. 2024;386:483-485.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/03/coronavirus-disease-research-references-by-amedeo-nov-3-24/

1. KURITZKES DR
   Remdesivir for Patients Hospitalized with COVID-19: Evidence of Effectiveness from Cohort Studies in the Omicron Era.
   Clin Infect Dis. 2024 Oct 24:ciae515. doi: 10.1093.
   PubMed        
2. WHITE EB, Grant L, Mak J, Olsho L, et al
   Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.
   Clin Infect Dis. 2024 Oct 24:ciae491. doi: 10.1093.
   PubMed         Abstract available
3. KALIL AC, Chandak A, Moore LSP, Ahuja N, et al
   Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19.
   Clin Infect Dis. 2024 Oct 25:ciae517. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

4. BRATCHER A, Kao SY, Chun K, Petropoulos CJ, et al
   Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021-February 2022.
   Emerg Infect Dis. 2024;30:2352-2361.
   PubMed         Abstract available
5. TAKAYAMA Y, Shimakawa Y, Matsuyama R, Chowell G, et al
   SARS-CoV-2 Infection in School Settings, Okinawa Prefecture, Japan, 2021-2022.
   Emerg Infect Dis. 2024;30:2343-2351.
   PubMed         Abstract available
6. DING K, Naqvi OH, Seeberger RJ, Bratzler DW, et al
   Spatiotemporal Ecologic Analysis of COVID-19 Vaccination Coverage and Outcomes, Oklahoma, USA, February 2020-December 2021.
   Emerg Infect Dis. 2024;30:2333-2342.
   PubMed         Abstract available
7. BURCKHARDT I, Burckhardt F
   Epidemiology of Streptococcus pyogenes Disease before, during, and after COVID-19 Pandemic, Germany, 2005-2023.
   Emerg Infect Dis. 2024;30:2435-2438.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. YAN J, McClure T, Aslam A, Bubb T, et al
   Impact of universal masking in reducing the risk of nosocomial respiratory viruses among people with cancer.
   Infect Control Hosp Epidemiol. 2024 Oct 25:1-5. doi: 10.1017/ice.2024.
   PubMed         Abstract available
9. BRAILITA DM, Soma M, Martinez R, Tyner L, et al
   The impact of statewide educational webinars on infection prevention and control knowledge and policy updates in acute and long-term care facilities during the COVID-19 pandemic: the Nebraska experience.
   Infect Control Hosp Epidemiol. 2024 Oct 23:1-4. doi: 10.1017/ice.2024.
   PubMed         Abstract available
10. SCHRANK GM, O’Hara LM, Pineles L, Popescu S, et al
    A survey of healthcare workers on the acceptance and value of personal protective equipment for patient care.
    Infect Control Hosp Epidemiol. 2024 Oct 23:1-5. doi: 10.1017/ice.2024.
    PubMed         Abstract available
11. IIJIMA K, Osako H, Iwata K
    Comparing the effectiveness of universal admission testing and risk-based testing at emergency admission for preventing nosocomial COVID-19: a multicenter retrospective cohort study in Japan.
    Infect Control Hosp Epidemiol. 2024 Oct 22:1-9. doi: 10.1017/ice.2024.
    PubMed         Abstract available
12. DE-LA-ROSA-MARTINEZ D, Vilar-Compte D, Martinez-Rivera N, Ochoa-Hein E, et al
    Multicenter study on Clostridioides difficile infections in Mexico: exploring the landscape.
    Infect Control Hosp Epidemiol. 2024 Oct 21:1-8. doi: 10.1017/ice.2024.
    PubMed         Abstract available
13. RAY MJ, Furuno JP, Strnad LC, Lofgren ET, et al
    Examining the impact of the COVID-19 pandemic on hospital-associated Clostridioides difficile infection.
    Infect Control Hosp Epidemiol. 2024 Oct 21:1-7. doi: 10.1017/ice.2024.
    PubMed         Abstract available

    Int J Infect Dis

14. AZHAR EI, Velavan TP, Rungsung I, Traore T, et al
    Corrigendum to “Middle East respiratory syndrome coronavirus-a 10-year (2012-2022) global analysis of human and camel infections, genomic sequences, lineages, and geographical origins” [International Journal of Infectious Diseases (2023), volume 131,
    Int J Infect Dis. 2024;149:107261.
    PubMed        

    J Virol

15. SONG X, Li Y, Wang C, Zhao Y, et al
    Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection.
    J Virol. 2024 Sep 10:e0130924. doi: 10.1128/jvi.01309.
    PubMed         Abstract available
16. CAILLAVA AJ, Alfonso V, Tejerina Cibello M, Demaria MA, et al
    A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.
    J Virol. 2024 Oct 23:e0101724. doi: 10.1128/jvi.01017.
    PubMed         Abstract available
17. ZHANG C, Jiang Q, Liu Z, Li N, et al
    SARS-CoV-2 NSP6 reduces autophagosome size and affects viral replication via sigma-1 receptor.
    J Virol. 2024 Oct 24:e0075424. doi: 10.1128/jvi.00754.
    PubMed         Abstract available

    JAMA

18. ANDERER S
    HHS Will Provide Free US-Made COVID-19 Tests to Households.
    JAMA. 2024 Oct 25. doi: 10.1001/jama.2024.21819.
    PubMed        

    Life Sci

19. DOS SANTOS L, Favaroni Mendes Salgado Ribeiro LA, Febba Gomes AC, Azinheira Nobrega Cruz N, et al
    ACE and ACE2 activities and polymorphisms assessment: A populational study from Ipaussu (SP, Brazil) during the COVID-19 pandemic.
    Life Sci. 2024;358:123157.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

20. MA KC, Castro J, Lambrou AS, Rose EB, et al
    Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages – United States, May 2023-September 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:938-945.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/10/27/coronavirus-disease-research-references-by-amedeo-october-27-24/

Source: Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00574-7/fulltext?rss=yes

Summary
Background
Existing studies on SARS-CoV-2 infection have mainly focused on severe clinical outcomes; understanding of the clinical severity profile of general community infections is poor. We aimed to assess and compare the clinical profiles of infections with SARS-CoV-2 omicron (B.1.1.529) subvariants in a representative community cohort in Hong Kong during periods of BA.2, BA.4/5, and XBB dominance.

Methods
In this prospective cohort study in Hong Kong, a representative community cohort of individuals aged at least 5 years were recruited by random-digit dialling and underwent weekly rapid antigen testing for SARS-CoV-2, irrespective of symptoms, during three periods from March 1, 2022, to Oct 31, 2023, in which the BA.2, BA.4/5, or XBB subvariants were dominant. We analysed the likelihood of symptoms, as well as the patterns, severity, and duration of symptoms and their associations with participant demographics and vaccination and infection histories.

Findings
1126 (11·0%) of 10 279 participants in the BA.2 period, 830 (6·6%) of 12 588 in the BA.4/5 period, and 633 (11·1%) of 5690 during the XBB period tested positive for SARS-CoV-2 infection on rapid antigen tests. Community infections were generally mild, with asymptomatic infections comprising 22·0–25·0% of infections. No hospitalisations or deaths occurred as a direct result of SARS-CoV-2 infection during the study period. Compared with children aged 5–17 years, a higher likelihood of being symptomatic on infection was found for adults aged 18–59 years during the period of BA.2 dominance and adults aged 60 years or older during XBB dominance. Most (>90·0%) participants with symptomatic infections reported respiratory and systemic symptoms. Up-to-date vaccination with a regimen containing the BNT162b2 vaccine, compared with those without an up-to-date vaccine, was associated with a reduced likelihood of symptoms on infection during the period of BA.2 dominance and of severe symptoms causing substantial disturbance to daily life (grade 3 symptoms) during periods of BA.2 and BA.4/5 dominance, whereas no association was observed during the period of XBB dominance. Previous SARS-CoV-2 infection was associated with a reduced likelihood of symptoms on infection during BA.4/5 and XBB dominance and of severe symptoms during XBB dominance. Reports of severe symptoms increased over the three periods, from 236 (27·7%) of 852 symptomatic participants during BA.2 dominance to 176 (37·1%) of 475 during XBB dominance. The duration of symptoms was longest in the BA.2 period (median 10·0 days [95% CI 9·0–10·0]) and similar in the other two periods (8·0 [8·0–9·0] during BA.4/5 dominance and 8·0 [8·0–9·0] during XBB dominance). A symptom duration of 60 days or longer was reported only during the period of BA.2 dominance, in six (0·7%) of 824 infections.

Interpretation
SARS-CoV-2 infections were generally mild, but not increasingly so, along the evolution of omicron subvariants in this highly vaccinated population. About a third of participants with symptomatic infections reported that the symptoms severely affected daily life even if they were not admitted to hospital, resulting in morbidity, absence from work or school due to illness, productivity loss, and increased medicoeconomic burden. A gradual reduction in the association of vaccines and increase in the association of previous infection with the symptom profile, possibly reflecting the effects of immune escape and waning, were observed over the study period.

____

https://etidioh.wordpress.com/2024/10/15/clinical-profile-analysis-of-sars-cov-2-community-infections-during-periods-with-omicron-ba2-ba4-5-and-xbb-dominance-in-hk-a-prospective-cohort-study/

1. VAN DER HORST D, Carter-Timofte ME, Danneels A, Silva da Costa L, et al
   Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses.
   Antiviral Res. 2024;231:106012.
   PubMed         Abstract available

   BMJ

2. IACOBUCCI G
   Covid inquiry hears harrowing evidence of effects on ICU staff.
   BMJ. 2024;386:q2125.
   PubMed        
3. NABAVI N
   Mix of relief and disappointment-striking a balance in the pay deal for resident doctors in England.
   BMJ. 2024;386:q2116.
   PubMed        
4. BOUM Y 2ND, Ndembi N
   Mpox needs a locally tailored global response.
   BMJ. 2024;386:q2094.
   PubMed        
5. DARLOW J
   Is the NHS “broken”? Staff haven’t given up, neither should our politicians.
   BMJ. 2024;386:q2130.
   PubMed        
6. DEMASI M
   Journal retracts Covaxin study after manufacturer sues for defamation.
   BMJ. 2024;386:q2119.
   PubMed        
7. Seven days in medicine: 18-24 September 2024.
   BMJ. 2024;386:q2087.
   PubMed        
8. TANNE JH
   Whooping cough: Fivefold rise in US cases spells return to pre-pandemic levels.
   BMJ. 2024;386:q2114.
   PubMed        
9. MAHASE E
   Politicians are failing to prepare for next pandemic, warns head of European health agency.
   BMJ. 2024;386:q2115.
   PubMed        
10. MAHASE E
    Covid inquiry: UKHSA chief is challenged on view that evidence for FFP3 masks is “weak”.
    BMJ. 2024;386:q2075.
    PubMed        

    Clin Infect Dis

11. TRAN KC, Asfar P, Cheng M, Demiselle J, et al
    Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.
    Clin Infect Dis. 2024;79:615-625.
    PubMed         Abstract available
12. FONG Y, Dang L, Zhang B, Fintzi J, et al
    Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
    Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093.
    PubMed         Abstract available
13. Correction to: Changes in the Appropriateness of US Outpatient Antibiotic Prescribing After the COVID-19 Outbreak: An Interrupted Time series Analysis of 2017-2021 Data.
    Clin Infect Dis. 2024 Sep 25:ciae455. doi: 10.1093.
    PubMed        

    Emerg Infect Dis

14. CHARLES H, Thorley K, Turner C, Bennet KF, et al
    Mpox Epidemiology and Vaccine Effectiveness, England, 2023.
    Emerg Infect Dis. 2024;30:2145-2148.
    PubMed         Abstract available
15. WERNIKE K, Mehl C, Aebischer A, Ulrich L, et al
    SARS-CoV-2 and Other Coronaviruses in Rats, Berlin, Germany, 2023.
    Emerg Infect Dis. 2024;30:2205-2208.
    PubMed         Abstract available
16. LININGER N, Falender R, Cieslak P, Novak A, et al
    Correlation between Viral Wastewater Concentration and Respiratory Tests, Oregon, USA.
    Emerg Infect Dis. 2024;30:2194-2196.
    PubMed         Abstract available

    Infect Control Hosp Epidemiol

17. BRANCH-ELLIMAN W, Banach DB, Batshon LJ, Dumyati G, et al
    SHEA position statement on pandemic preparedness for policymakers: pandemic data collection, maintenance, and release.
    Infect Control Hosp Epidemiol. 2024;45:821-825.
    PubMed         Abstract available
18. HSU VP, Pergam SA, Shenoy ES, Banach DB, et al
    SHEA position statement on pandemic preparedness for policymakers: emerging infectious threats.
    Infect Control Hosp Epidemiol. 2024;45:818-820.
    PubMed        
19. DEWITT ME, Sampson MM, Kester S, MacNeill E, et al
    Racial disparities in central line-associated bloodstream infections: the impact of the COVID-19 pandemic.
    Infect Control Hosp Epidemiol. 2024 Sep 26:1-5. doi: 10.1017/ice.2024.
    PubMed         Abstract available

    Int J Infect Dis

20. LEE JA, Jang H, Ahn SM, Seong JE, et al
    Estimates of Vaccine Effectiveness of the Updated Monovalent XBB.1.5 COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection, Hospitalization, and Receipt of Oxygen Therapy in South Korea – October 26 to December 31, 2023.
    Int J Infect Dis. 2024 Sep 20:107249. doi: 10.1016/j.ijid.2024.107249.
    PubMed         Abstract available
21. TAKAHASHI H, Morikawa M, Satake Y, Nagamatsu H, et al
    Diagnostic Utility of Pharyngeal Follicular Structures in COVID-19: A Large-scale Cross-Sectional Study.
    Int J Infect Dis. 2024 Sep 21:107244. doi: 10.1016/j.ijid.2024.107244.
    PubMed         Abstract available

    J Infect

22. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    PubMed         Abstract available
23. VEGA-PIRIS L, Carretero SG, Mayordomo JL, Zarzuelo MBR, et al
    Severity of Respiratory Syncytial Virus compared with SARS-CoV-2 and Influenza among hospitalised adults >/=65 years.
    J Infect. 2024 Sep 26:106292. doi: 10.1016/j.jinf.2024.106292.
    PubMed         Abstract available
24. CHEN X, Balliew J, Bauer CX, Deegan J, et al
    Revealing patterns of SARS-CoV-2 variant emergence and evolution using RBD amplicon sequencing of wastewater.
    J Infect. 2024 Sep 26:106284. doi: 10.1016/j.jinf.2024.106284.
    PubMed         Abstract available
25. RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al
    N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.
    J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288.
    PubMed         Abstract available
26. SABATE-ELABBADI A, Brolon L, Brun-Buisson C, Guillemot D, et al
    Trends in hospitalisations for lower respiratory infections after the COVID-19 pandemic in France.
    J Infect. 2024 Sep 26:106287. doi: 10.1016/j.jinf.2024.106287.
    PubMed         Abstract available

    J Med Virol

27. KUHN D, Heinen N, Sutter K, Herrmann ST, et al
    Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival.
    J Med Virol. 2024;96:e29935.
    PubMed         Abstract available
28. LOVELL JF, Miura K, Baik YO, Lee C, et al
    Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.
    J Med Virol. 2024;96:e29927.
    PubMed         Abstract available
29. LI H, Yang Y, Tao R, Shang S, et al
    Analyzing infections caused by 11 respiratory pathogens in children: Pre- and post-COVID-19 pandemic trends in China.
    J Med Virol. 2024;96:e29929.
    PubMed         Abstract available
30. HORI M, Hayama-Terada M, Kitamura A, Hosozawa M, et al
    Risk factors for post-coronavirus disease condition in the Alpha-, Delta-, and Omicron-dominant waves among adults in Japan: A population-based matched case-control study.
    J Med Virol. 2024;96:e29928.
    PubMed         Abstract available

    J Virol

31. KANG JS, Zhou K, Wang H, Tang S, et al
    Architectural organization and in situ fusion protein structure of lymphocytic choriomeningitis virus.
    J Virol. 2024 Sep 27:e0064024. doi: 10.1128/jvi.00640.
    PubMed         Abstract available

    JAMA

32. ANDERER S
    Caseload Strain Contributed to 1 in 5 COVID-19 Deaths at US Hospitals.
    JAMA. 2024 Sep 27. doi: 10.1001/jama.2024.19687.
    PubMed        

    Lancet

33. IMANI-MUSIMWA P, Ververs M
    Mpox and breastmilk: for once, can we act in time?
    Lancet. 2024 Sep 13:S0140-6736(24)01881-6. doi: 10.1016/S0140-6736(24)01881.
    PubMed        
34. HORTON R
    Offline: Xenotransplantation-a new era beckons.
    Lancet. 2024;404:1181.
    PubMed        
35. ROMANELLO M, Costello A
    The Lancet Countdown on health and climate change: competing interests and optimism bias – Authors’ reply.
    Lancet. 2024;404:1197-1198.
    PubMed        
36. BRINK N, Chersich MF
    The Lancet Countdown on health and climate change: competing interests and optimism bias.
    Lancet. 2024;404:1196.
    PubMed        
37. BUTLER CD, Combs Bowles D, Hanigan IC, Harmer A, et al
    The Lancet Countdown on health and climate change: competing interests and optimism bias.
    Lancet. 2024;404:1196-1197.
    PubMed        
38. ROMANELLO M, Beggs PJ, Cai W, Gordon-Strachan G, et al
    The Lancet Countdown on health and climate change: representation matters – Authors’ reply.
    Lancet. 2024;404:1195-1196.
    PubMed        
39. STREET R, Wright CY
    The Lancet Countdown on health and climate change: representation matters.
    Lancet. 2024;404:1194.
    PubMed        

    Lancet Infect Dis

40. DAS M
    Understanding outbreak preparedness.
    Lancet Infect Dis. 2024;24:1079.
    PubMed        
41. OLBRICH L, Franckling-Smith Z, Larsson L, Sabi I, et al
    Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494.
    PubMed         Abstract available
42. LAWSON M
    Globalisation and COVID-19.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00621.
    PubMed        
43. TERSTAPPEN J, Hak SF, Bhan A, Bogaert D, et al
    The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
    Lancet Infect Dis. 2024 Sep 23:S1473-3099(24)00455.
    PubMed         Abstract available
44. FIGUEROA AL, Torres D, Reyes-Acuna C, Matherne P, et al
    Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00501.
    PubMed         Abstract available
45. WANG WX, Zhu FC
    COVID-19 immunisation strategies for adolescents.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00563.
    PubMed        
46. HAPPLE C, Hoffmann M, Kempf A, Nehlmeier I, et al
    Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination.
    Lancet Infect Dis. 2024 Sep 25:S1473-3099(24)00603.
    PubMed        

    MMWR Morb Mortal Wkly Rep

47. HAVERS FP, Whitaker M, Chatwani B, Patton ME, et al
    COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months – COVID-NET, 12 States, October 2022-April 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:830-836.
    PubMed         Abstract available
48. HILL HA, Yankey D, Elam-Evans LD, Mu Y, et al
    Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 – National Immunization Survey-Child, United States, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:844-853.
    PubMed         Abstract available

    Nature

49. The youngest among us fight COVID-19 in their own way.
    Nature. 2024 Sep 24. doi: 10.1038/d41586-024-03091.
    PubMed   

https://etidioh.wordpress.com/2024/09/29/coronavirus-disease-research-references-amedeo-september-29-24/

1. June 1 Highlight.
   Am J Respir Crit Care Med. 2024;209:xxxvii-xxxviii.
   PubMed        

   BMJ

2. REYNOLDS C, Naqvi H
   Better use of data can help to prevent future deaths.
   BMJ. 2024;385:q1181.
   PubMed        
3. LYNN E
   May top picks: politics, psychological safety, and creativity.
   BMJ. 2024;385:q1166.
   PubMed        
4. TAYLOR L
   Pandemic treaty: panel calls for “reset” to talks as negotiators miss deadline.
   BMJ. 2024;385:q1193.
   PubMed        
5. LIMB M
   Labour’s pledge to clear NHS waiting list within five years will be tough to achieve, say leaders.
   BMJ. 2024;385:q1186.
   PubMed        
6. KMIETOWICZ Z
   Junior doctors in England announce five day walkout ahead of general election.
   BMJ. 2024;385:q1183.
   PubMed        
7. MAHASE E
   GPs could threaten mass resignation over NHS contract.
   BMJ. 2024;385:q1182.
   PubMed        
8. WISE J
   Improving infection prevention could avoid 750 000 deaths a year, say experts.
   BMJ. 2024;385:q1163.
   PubMed        
9. DYER O
   Covid-19: South African disclosures reveal secretive world of nations’ vaccine contracts.
   BMJ. 2024;385:q1172.
   PubMed        

   Clin Infect Dis

10. WOLFE DN, Arangies E, David GL, Armstrong B, et al
    Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study Designs.
    Clin Infect Dis. 2024 May 28:ciae286. doi: 10.1093.
    PubMed         Abstract available
11. HILL JA, Martens MJ, Young JH, Bhavsar K, et al
    SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
    Clin Infect Dis. 2024 May 27:ciae291. doi: 10.1093.
    PubMed         Abstract available

    Int J Infect Dis

12. REEKIE J, Stovring H, Nielsen H, Johansen IS, et al
    Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2.
    Int J Infect Dis. 2024 May 25:107111. doi: 10.1016/j.ijid.2024.107111.
    PubMed         Abstract available

    Intensive Care Med

13. OUD L
    Long-term outcomes of critically ill patients with hematological malignancies: what is the impact of the coronavirus disease 2019 pandemic?
    Intensive Care Med. 2024 May 28. doi: 10.1007/s00134-024-07493.
    PubMed        

    J Med Virol

14. HAN Y, Ma Y, Wang Z, Feng F, et al
    TMPRSS13 promotes the cell entry of swine acute diarrhea syndrome coronavirus.
    J Med Virol. 2024;96:e29712.
    PubMed         Abstract available
15. BORGOGNA C, Ferrante D, Rosso G, Guglielmetti G, et al
    A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
    J Med Virol. 2024;96:e29710.
    PubMed         Abstract available
16. PAVIA G, Quirino A, Marascio N, Veneziano C, et al
    Persistence of SARS-CoV-2 infection and viral intra- and inter-host evolution in COVID-19 hospitalized patients.
    J Med Virol. 2024;96:e29708.
    PubMed         Abstract available
17. KOW CS, Ramachandram DS, Hasan SS, Thiruchelvam K, et al
    Antibiotics in COVID-19: Unveiling disturbing truths through critical scrutiny.
    J Med Virol. 2024;96:e29720.
    PubMed        
18. CHEN IW, Yu TS, Lin CH, Hung KC, et al
    Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis.
    J Med Virol. 2024;96:e29718.
    PubMed        

    J Travel Med

19. TAY M, Lee B, Ismail MH, Yam J, et al
    Usefulness of aircraft and airport wastewater for monitoring multiple pathogens including SARS-CoV-2 variants.
    J Travel Med. 2024 May 30:taae074. doi: 10.1093.
    PubMed         Abstract available

    J Virol

20. MARIZZI C, Ajayi PK, McMahon R, Meade PS, et al
    A community science approach to public health and public trust in science.
    J Virol. 2024 May 29:e0082524. doi: 10.1128/jvi.00825.
    PubMed         Abstract available
21. RAHMAN SM, Buchholz DW, Imbiakha B, Jager MC, et al
    Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs.
    J Virol. 2024 May 30:e0006624. doi: 10.1128/jvi.00066.
    PubMed         Abstract available
22. KARMAKAR S, Das Sarma J
    Human coronavirus OC43 infection remodels connexin 43-mediated gap junction intercellular communication in vitro.
    J Virol. 2024 May 31:e0047824. doi: 10.1128/jvi.00478.
    PubMed         Abstract available

    Lancet

23. THORNTON J
    Infected blood report release marks a day of shame for the UK.
    Lancet. 2024;403:2276-2277.
    PubMed        
24. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    PubMed         Abstract available
25. THE LANCET
    Cyberattacks on health care-a growing threat.
    Lancet. 2024;403:2263.
    PubMed        
26. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    PubMed         Abstract available
27. PATERLINI M
    Warnings over Italian health-care devolution.
    Lancet. 2024;403:2279.
    PubMed        

    Lancet Infect Dis

28. HALL P
    Highlights of ESCMID Global 2024.
    Lancet Infect Dis. 2024;24:e357.
    PubMed        
29. VENKATESAN P
    Alasdair Macintosh Geddes.
    Lancet Infect Dis. 2024;24:577.
    PubMed        

    Life Sci

30. PETRY J, Weiser T, Griesbaum L, Schroder K, et al
    1.8-cineole prevents platelet activation and aggregation by activating the cAMP pathway via the adenosine A(2A) receptor.
    Life Sci. 2024 May 27:122746. doi: 10.1016/j.lfs.2024.122746.
    PubMed         Abstract available

    N Engl J Med

31. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed        
32. HALABI S, Gostin LO, Egbokhare O, Kavanagh MM, et al
    Global Health Law for a Safer and Fairer World.
    N Engl J Med. 2024;390:1925-1931.
    PubMed        

    Nature

33. HAN Y, Duan X, Yang L, Nilsson-Payant BE, et al
    Author Correction: Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.
    Nature. 2024 May 29. doi: 10.1038/s41586-024-07593.
    PubMed        

    Science

34. VAN DER LINDEN S, Kyrychenko Y
    A broader view of misinformation reveals potential for intervention.
    Science. 2024;384:959-960.
    PubMed         Abstract available
35. ALLEN J, Watts DJ, Rand DG
    Quantifying the impact of misinformation and vaccine-skeptical content on Facebook.
    Science. 2024;384:eadk3451.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/06/01/coronavirus-disease-research-references-by-amedeo-june-1-24/

1. MELLO MM, Jiang D, Platt E, Moran-McCabe K, et al.
   Legal infrastructure for pandemic response: lessons not learnt in the US.
   BMJ. 2024;384:e076269.
   PubMed: https://www.amedeo.com/p2.php?id=38346813&s=cov&pm=2
    
   Share: https://m.amedeo.com/38346813
2. Seven days in medicine: 31 Jan to 6 Feb 2024.
   BMJ. 2024;384:q299.
   PubMed: https://www.amedeo.com/p2.php?id=38331441&s=cov&pm=2
    
   Share: https://m.amedeo.com/38331441
3. IACOBUCCI G.
   Long covid: Online rehabilitation can improve quality of life, study reports.
   BMJ. 2024;384:q346.
   PubMed: https://www.amedeo.com/p2.php?id=38331437&s=cov&pm=2
    
   Share: https://m.amedeo.com/38331437
4. COLSON P, Delerce J, Pontarotti P, Devaux C, et al.
   Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir:
   Selection not induction.
   J Med Virol. 2024;96:e29462.
   PubMed: https://www.amedeo.com/p2.php?id=38363015&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38363015
5. SADAT LARIJANI M, Javadi A, Eskandari SE, Doroud D, et al.
   The impact of ABO blood types on humoral immunity responses and antibody
   persistency after different COVID-19 vaccine regimens.
   J Med Virol. 2024;96:e29438.
   PubMed: https://www.amedeo.com/p2.php?id=38353517&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38353517
6. CENAT JM, Farahi SMMM, Dalexis RD, Yaya S, et al.
   COVID-19 vaccine uptake, conspiracy theories, and health literacy among Black
   individuals in Canada: Racial discrimination, confidence in health, and COVID-19
   stress as mediators.
   J Med Virol. 2024;96:e29467.
   PubMed: https://www.amedeo.com/p2.php?id=38348886&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38348886
7. KWOK KO, Wei WI, Mcneil EB, Tang A, et al.
   Comparative analysis of symptom profile and risk of death associated with
   infection by SARS-CoV-2 and its variants in Hong Kong.
   J Med Virol. 2024;96:e29326.
   PubMed: https://www.amedeo.com/p2.php?id=38345166&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38345166
8. KIM D, Kim M, Kim J, Baek K, et al.
   A mouse xenograft long-term replication yields a SARS-CoV-2 Delta mutant with
   increased lethality.
   J Med Virol. 2024;96:e29459.
   PubMed: https://www.amedeo.com/p2.php?id=38345153&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38345153
9. ZHAN H, Xie Y, Liu Y, Cheng L, et al.
   Omicron BA.4/5 neutralization and cell-mediated immune responses in relation to
   baseline immune status and breakthrough infection among PLWH: A follow-up cohort
   study.
   J Med Virol. 2024;96:e29446.
   PubMed: https://www.amedeo.com/p2.php?id=38345110&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38345110
10. ZENG G, Zhang Z, Wang L, Li J, et al.
    Risk factors of long COVID 6-12 months after infection with the Omicron variant
    among nonhospitalized patients.
    J Med Virol. 2023;95:e29235.
    PubMed: https://www.amedeo.com/p2.php?id=37970745&s=cov&pm=2
     
    Share: https://m.amedeo.com/37970745
11. LI Z, Lai Y, Qiu R, Tang W, et al.
    Hyperacetylated microtubules assist porcine deltacoronavirus nsp8 to degrade MDA5
    via SQSTM1/p62-dependent selective autophagy.
    J Virol. 2024 Feb 14:e0000324. doi: 10.1128/jvi.00003.
    PubMed: https://www.amedeo.com/p2.php?id=38353538&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38353538
12. RUBIN R.
    When It Comes to SARS-CoV-2 Clearance, People Who are Immunocompromised Are Not
    All Alike.
    JAMA. 2024 Feb 14. doi: 10.1001/jama.2024.1014.
    PubMed: https://www.amedeo.com/p2.php?id=38353960&s=cov&pm=2
     
    Share: https://m.amedeo.com/38353960
13. WALLER BY, Joseph VA, Keyes KM.
    Racial inequities in homicide rates and homicide methods among Black and White
    women aged 25-44 years in the USA, 1999-2020: a cross-sectional time series
    study.
    Lancet. 2024 Feb 8:S0140-6736(23)02279-1. doi: 10.1016/S0140-6736(23)02279.
    PubMed: https://www.amedeo.com/p2.php?id=38342127&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38342127
14. VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al.
    Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
    N Engl J Med. 2024;390:589-600.
    PubMed: https://www.amedeo.com/p2.php?id=38354138&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38354138
15. The immune markers that predict who can keep SARS-CoV-2 in check.
    Nature. 2024 Feb 13. doi: 10.1038/d41586-024-00411.
    PubMed: https://www.amedeo.com/p2.php?id=38351161&s=cov&pm=2
     
    Share: https://m.amedeo.com/38351161
16. GAGLIARDINI R, Giacomelli A, Bozzi G, D’Arminio Monforte A, et al.
    Impact of COVID-19 pandemic on retention in care of native and migrant people
    with HIV in the ICONA cohort.
    Travel Med Infect Dis. 2024;58:102691.
    PubMed: https://www.amedeo.com/p2.php?id=38336335&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38336335
17. HOFMEYER KA, Ventura CL, Armstrong KL, Houchens CR, et al.
    Project NexGen: Developing the Next Generation of COVID-19 Vaccines and
    Therapeutics to Respond to the Present and Prepare for the Future.
    Clin Infect Dis. 2024 Feb 13:ciae073. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38356144&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38356144
18. MACHKOVECH HM, Hahn AM, Garonzik Wang J, Grubaugh ND, et al.
    Persistent SARS-CoV-2 infection: significance and implications.
    Lancet Infect Dis. 2024 Feb 7:S1473-3099(23)00815.
    PubMed: https://www.amedeo.com/p2.php?id=38340735&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38340735
19. JIAO Z, Wang P, Hu X, Chen Y, et al.
    Feline infectious peritonitis virus ORF7a is a virulence factor involved in
    inflammatory pathology in cats.
    Antiviral Res. 2024;222:105794.
    PubMed: https://www.amedeo.com/p2.php?id=38176470&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38176470

https://etidioh.wordpress.com/2024/02/18/coronavirus-disease-research-references-by-amedeo-february-18-24/

1. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
   Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
   Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
   PubMed         Abstract available
2. BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al
   Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
   Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813.
   PubMed         Abstract available
3. BOND ACS, Crocker MA, Wilczek MP, DuShane JK, et al
   High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.
   Antiviral Res. 2024 Jan 19:105817. doi: 10.1016/j.antiviral.2024.105817.
   PubMed         Abstract available
4. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
   An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
   Antiviral Res. 2024;222:105815.
   PubMed         Abstract available

   BMJ

5. WATERS A
   Covid-19: Doctors instruct law firm in bid for compensation after developing long covid.
   BMJ. 2024;384:q188.
   PubMed        
6. BRINDLEY P
   Essential workers during covid-19: how quickly we forget.
   BMJ. 2024;384:q179.
   PubMed        
7. WISE J
   UK covid inquiry: Scotland’s infection control and care home policies face scrutiny.
   BMJ. 2024;384:q162.
   PubMed        

   Clin Infect Dis

8. RYBOLT L, Oehler RL, Khalil FK, Khalil B, et al
   A 22-Year-Old With a Left Apical Chest Mass.
   Clin Infect Dis. 2024;78:199-201.
   PubMed        
9. HSUEH K, Teherani A, Guzman-Cottrill JA
   The Leaders in Epidemiology, Antimicrobial Stewardship, and Public Health (LEAP) Fellowship, a Novel Training Program in Public Health for Infectious Diseases Physicians.
   Clin Infect Dis. 2024 Jan 24:ciad787. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

10. JUSTMAN J, Skalland T, Moore A, Amos CI, et al
    Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021(1).
    Emerg Infect Dis. 2024;30:245-254.
    PubMed         Abstract available
11. PORTER SM, Hartwig AE, Bielefeldt-Ohmann H, Marano JM, et al
    Experimental SARS-CoV-2 Infection of Elk and Mule Deer.
    Emerg Infect Dis. 2024;30:354-357.
    PubMed         Abstract available
12. TORI ME, Chontos-Komorowski J, Stacy J, Lamson DM, et al
    Identification of Large Adenovirus Infection Outbreak at University by Multipathogen Testing, South Carolina, USA, 2022.
    Emerg Infect Dis. 2024;30:358-362.
    PubMed         Abstract available
13. TAKEMURA T, Ankhanbaatar U, Settypalli TBK, Purevtseren D, et al
    SARS-CoV-2 Infection in Beaver Farm, Mongolia, 2021.
    Emerg Infect Dis. 2024;30:391-394.
    PubMed         Abstract available
14. HODGES NF, Sparrer M, Sherman T, Mayer T, et al
    Integrating Veterinary Diagnostic Laboratories for Emergency Use Testing during Pandemics(1).
    Emerg Infect Dis. 2024;30:386-388.
    PubMed         Abstract available

    J Infect

15. LIU Y, Sun R, Zhang H, Huang J, et al
    Trends and predictions of tuberculosis notification in mainland China during and after the COVID-19 pandemic.
    J Infect. 2023;87:e100-e103.
    PubMed        
16. AO G, Li T, Nasr B, Wang Y, et al
    The effect of dupilumab on clinical outcomes in patients with COVID-19: A meta-analysis.
    J Infect. 2023;87:e107-e109.
    PubMed        
17. MURRAY JM, Murray DD, Schvoerer E, Akand EH, et al
    SARS-CoV-2 Delta and Omicron community transmission networks as added value to contact tracing.
    J Infect. 2024 Jan 17:S0163-4453(24)00023-9. doi: 10.1016/j.jinf.2024.
    PubMed         Abstract available

    J Med Virol

18. YANG X, Wang Y, Liang Z, Cui T, et al
    Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
    J Med Virol. 2024;96:e29417.
    PubMed         Abstract available
19. ZHANG T, Magazine N, McGee MC, Carossino M, et al
    Th2 and Th17-associated immunopathology following SARS-CoV-2 breakthrough infection in Spike-vaccinated ACE2-humanized mice.
    J Med Virol. 2024;96:e29408.
    PubMed         Abstract available
20. JIA J, Garbarino E, Wang Y, Li J, et al
    Generation of SARS-CoV-2 spike receptor binding domain mutants and functional screening for immune evaders using a novel lentivirus-based system.
    J Med Virol. 2024;96:e29425.
    PubMed         Abstract available
21. SUN Y, Zhou J, Nie W, Tian D, et al
    Study on the epidemiological characteristics of enterovirus among pediatric patients in Hangzhou, China: A comparison between the pre-COVID-19, COVID-19 pandemic, and post-COVID-19 periods.
    J Med Virol. 2024;96:e29412.
    PubMed         Abstract available

    J Travel Med

22. CHIU NC, Chi H, Weng SL, Lin CY, et al
    Unprecedented dengue outbreak in Taiwan following COVID-19.
    J Travel Med. 2024 Jan 21:taae015. doi: 10.1093.
    PubMed        
23. SOHAIL A, Anders KL, McGuinness SL, Leder K, et al
    The epidemiology of imported and locally-acquired dengue in Australia, 2012-2022.
    J Travel Med. 2024 Jan 18:taae014. doi: 10.1093.
    PubMed         Abstract available

    J Virol

24. DEY S, Mondal A
    Unveiling the role of host kinases at different steps of influenza A virus life cycle.
    J Virol. 2024 Jan 4:e0119223. doi: 10.1128/jvi.01192.
    PubMed         Abstract available
25. ZHANG S, Wang J, Liu X, Kan Z, et al
    Pemetrexed alleviates piglet diarrhea by blocking the interaction between porcine epidemic diarrhea virus nucleocapsid protein and Ezrin.
    J Virol. 2024;98:e0162523.
    PubMed         Abstract available

    Lancet

26. MCCLOSKEY B, Saito T, Shimada S, Ikenoue C, et al
    The Tokyo 2020 and Beijing 2022 Olympic Games held during the COVID-19 pandemic: planning, outcomes, and lessons learnt.
    Lancet. 2024 Jan 17:S0140-6736(23)02635-1. doi: 10.1016/S0140-6736(23)02635.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

27. MONACH PA, Anand ST, Fillmore NR, La J, et al
    Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 – Veterans Health Administration, March-September 2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:57-61.
    PubMed         Abstract available

    N Engl J Med

28. BORGHESI A, Casanova JL
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:384-385.
    PubMed        
29. SENEFELD JW, Henderson JP, Joyner MJ
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:385.
    PubMed        
30. CASADEVALL A, Shoham S, Pirofski LA
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:385-386.
    PubMed        
31. MISSET B, Desmecht D, Laterre PF
    Convalescent Plasma for Covid-19-Induced ARDS. Reply.
    N Engl J Med. 2024;390:386.
    PubMed        

    Radiology

32. LEE JE, Jin KN, Hong H, Jeong YJ, et al
    Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection.
    Radiology. 2024;310:e231928.
    PubMed         Abstract available
33. WELLS AU
    COVID-19 Vaccine Efficacy Over Time: Severe Disease in Hospitalized Patients.
    Radiology. 2024;310:e233340.
    PubMed        

    Science

34. RUF W
    Immune damage in Long Covid.
    Science. 2024;383:262-263.
    PubMed         Abstract available
35. LESLIE M
    SARS-CoV-2 sneezing explained.
    Science. 2024;383:354.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/01/29/coronavirus-disease-research-references-by-amedeo-january-29-24/

1. KERCHBERGER VE.
   Host Response to Infection: Not All Lymphopenia Is Created Equal in SARS-CoV-2.
   Am J Respir Crit Care Med. 2024 Jan 8. doi: 10.1164/rccm.202312-2265.
   PubMed: https://www.amedeo.com/p2.php?id=38190496&s=cov&pm=2
    
   Share: https://m.amedeo.com/38190496
2. WU Q, Tong J, Zhang B, Zhang D, et al.
   Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents.
   Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-1754.
   PubMed: https://www.amedeo.com/p2.php?id=38190711&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38190711
3. O’DOWD A.
   Covid-19 has cut UK life expectancy by around half a year, data suggest.
   BMJ. 2024;384:q78.
   PubMed: https://www.amedeo.com/p2.php?id=38216221&s=cov&pm=2
    
   Share: https://m.amedeo.com/38216221
4. MAHASE E.
   Covid-19: NICE plans to expand Paxlovid eligibility to 1.4 million more people.
   BMJ. 2024;384:q59.
   PubMed: https://www.amedeo.com/p2.php?id=38212056&s=cov&pm=2
    
   Share: https://m.amedeo.com/38212056
5. Update to living systematic review on SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission.
   BMJ. 2024;384:p2929.
   PubMed: https://www.amedeo.com/p2.php?id=38199645&s=cov&pm=2
    
   Share: https://m.amedeo.com/38199645
6. SLAUNWHITE A, Min JE, Palis H, Urbanoski K, et al.
   Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.
   BMJ. 2024;384:e076336.
   PubMed: https://www.amedeo.com/p2.php?id=38199614&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38199614
7. TANNE JH.
   Covid-19: Some US states and hospitals recommend masks again.
   BMJ. 2024;384:q26.
   PubMed: https://www.amedeo.com/p2.php?id=38182176&s=cov&pm=2
    
   Share: https://m.amedeo.com/38182176
8. EGBELOWO OF, Fox SJ, Gibson GC, Meyers LA, et al.
   Model for Interpreting Discordant SARS-CoV-2 Diagnostic Test Results.
   Emerg Infect Dis. 2024;30.
   PubMed: https://www.amedeo.com/p2.php?id=38217064&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38217064
9. EALES O, Plank MJ, Cowling BJ, Howden BP, et al.
   Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic.
   Emerg Infect Dis. 2024;30.
   PubMed: https://www.amedeo.com/p2.php?id=38190760&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38190760
10. JEON S, Watson-Lewis L, Rainisch G, Chiu CC, et al.
    Adapting COVID-19 Contact Tracing Protocols to Accommodate Resource Constraints, Philadelphia, Pennsylvania, USA, 2021.
    Emerg Infect Dis. 2024;30.
    PubMed: https://www.amedeo.com/p2.php?id=38181801&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38181801
11. BAI Y, Du Z, Wang L, Lau EHY, et al.
    Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
    Emerg Infect Dis. 2024;30.
    PubMed: https://www.amedeo.com/p2.php?id=38181800&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38181800
12. HU L, Yang Y, Lin J, Yan Q, et al.
    Epidemiological characteristics of respiratory syncytial virus infection in pediatric patients before, during the COVID-19 pandemic and after easing of COVID-19 restrictive measures in China.
    J Med Virol. 2024;96:e29374.
    PubMed: https://www.amedeo.com/p2.php?id=38197487&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38197487
13. ZHANG Y, Ma Y, Sun W, Zhou X, et al.
    Exploring gut-lung axis crosstalk in SARS-CoV-2 infection: Insights from a hACE2 mouse model.
    J Med Virol. 2024;96:e29336.
    PubMed: https://www.amedeo.com/p2.php?id=38193530&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38193530
14. FAVRESSE J, Gillot C, Closset M, Cabo J, et al.
    Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster.
    J Med Virol. 2024;96:e29365.
    PubMed: https://www.amedeo.com/p2.php?id=38185981&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38185981
15. CHOI CY, Gadhave K, Villano J, Pekosz A, et al.
    Generation and characterization of a humanized ACE2 mouse model to study long-term impacts of SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29349.
    PubMed: https://www.amedeo.com/p2.php?id=38185937&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38185937
16. LEE HM, Shih PC, Wei JC.
    Comment on Shao et al.’s “Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic”.
    J Med Virol. 2024;96:e29383.
    PubMed: https://www.amedeo.com/p2.php?id=38180246&s=cov&pm=2
     
    Share: https://m.amedeo.com/38180246
17. LI J, Zhang K, Lin G, Li J, et al.
    CRISPR-Cas system: A promising tool for rapid detection of SARS-CoV-2 variants.
    J Med Virol. 2024;96:e29356.
    PubMed: https://www.amedeo.com/p2.php?id=38180237&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38180237
18. CAPELLI N, Domitien Payet L, Alcocer Cordellat C, Pisoni A, et al.
    SARS-CoV-2 nucleocapsid antigen in plasma of children hospitalized for COVID-19 or with incidental detection of SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29358.
    PubMed: https://www.amedeo.com/p2.php?id=38180230&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38180230
19. MOORE JE, Millar BC.
    Improving health literacy of passengers of cruise ships: readability of passenger-facing COVID-19 information provided by commercial cruise lines-an infodemiology study.
    J Travel Med. 2024 Jan 11:taae006. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38206876&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206876
20. JAMES ER, Church LWP, Hoffman SL, Robertson BD, et al.
    Piloting delivery of PfSPZ vaccines for malaria through a cryogenic vaccine cold chain to travel and military medicine clinics.
    J Travel Med. 2024 Jan 11:taae007. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38206875&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206875
21. DULIN H, Barre RS, Xu D, Neal A, et al.
    Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
    J Virol. 2024 Jan 11:e0157123. doi: 10.1128/jvi.01571.
    PubMed: https://www.amedeo.com/p2.php?id=38206036&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206036
22. BERTZBACH LD, Seddar L, von Stromberg K, Ip W-H, et al.
    The adenovirus DNA-binding protein DBP.
    J Virol. 2024 Jan 10:e0188523. doi: 10.1128/jvi.01885.
    PubMed: https://www.amedeo.com/p2.php?id=38197632&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38197632
23. YIN L, Liu X, Yao Y, Yuan M, et al.
    Gut microbiota-derived butyrate promotes coronavirus TGEV infection through impairing RIG-I-triggered local type I interferon responses via class I HDAC inhibition.
    J Virol. 2024 Jan 10:e0137723. doi: 10.1128/jvi.01377.
    PubMed: https://www.amedeo.com/p2.php?id=38197629&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38197629
24. RUBIN R.
    As COVID-19 Cases Surge, Here’s What to Know About JN.1, the Latest SARS-CoV-2 “Variant of Interest”.
    JAMA. 2024 Jan 12. doi: 10.1001/jama.2023.27841.
    PubMed: https://www.amedeo.com/p2.php?id=38214935&s=cov&pm=2
     
    Share: https://m.amedeo.com/38214935
25. RUBIN R.
    From “Immunity Debt” to “Immunity Theft”-How COVID-19 Might Be Tied to Recent Respiratory Disease Surges.
    JAMA. 2024 Jan 10. doi: 10.1001/jama.2023.26608.
    PubMed: https://www.amedeo.com/p2.php?id=38198193&s=cov&pm=2
     
    Share: https://m.amedeo.com/38198193
26. KAPOOR N, Dietz C, Buettner BP.
    An Incarcerated Individual With Weight Loss and Interstitial Pulmonary Infiltrates.
    JAMA. 2024 Jan 8. doi: 10.1001/jama.2023.24260.
    PubMed: https://www.amedeo.com/p2.php?id=38190148&s=cov&pm=2
     
    Share: https://m.amedeo.com/38190148
27. MARKS P, Califf R.
    Is Vaccination Approaching a Dangerous Tipping Point?
    JAMA. 2024 Jan 5. doi: 10.1001/jama.2023.27685.
    PubMed: https://www.amedeo.com/p2.php?id=38180773&s=cov&pm=2
     
    Share: https://m.amedeo.com/38180773
28. PAYNE AB, Novosad S, Wiegand RE, Najdowski M, et al.
    Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged >/=65 Years and Those with End Stage Renal Disease – United States, September 2022-March 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:16-23.
    PubMed: https://www.amedeo.com/p2.php?id=38206877&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206877
29. CHA MJ, Solomon JJ, Lee JE, Choi H, et al.
    Chronic Lung Injury after COVID-19 Pneumonia: Clinical, Radiologic, and Histopathologic Perspectives.
    Radiology. 2024;310:e231643.
    PubMed: https://www.amedeo.com/p2.php?id=38193836&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38193836
30. COHEN J.
    Covid’s cold cousins.
    Science. 2024;383:141-145.
    PubMed: https://www.amedeo.com/p2.php?id=38207045&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38207045
31. NACHMAN S, Aldrovandi G.
    Breastfeeding in the United States Among Women With HIV: Con Viewpoint.
    Clin Infect Dis. 2024 Jan 8:ciad778. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38185124&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38185124
32. COSSMANN A, Hoffmann M, Stankov MV, Lurken K, et al.
    Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00783.
    PubMed: https://www.amedeo.com/p2.php?id=38211602&s=cov&pm=2
     
    Share: https://m.amedeo.com/38211602
33. KOSUGI Y, Kaku Y, Hinay AA Jr, Guo Z, et al.
    Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00784.
    PubMed: https://www.amedeo.com/p2.php?id=38211599&s=cov&pm=2
     
    Share: https://m.amedeo.com/38211599
34. HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al.
    Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study.
    Lancet Infect Dis. 2024 Jan 5:S1473-3099(23)00746.
    PubMed: https://www.amedeo.com/p2.php?id=38190834&s=cov&pm=2
     
    Share: https://m.amedeo.com/38190834
35. KAKU Y, Okumura K, Padilla-Blanco M, Kosugi Y, et al.
    Virological characteristics of the SARS-CoV-2 JN.1 variant.
    Lancet Infect Dis. 2024 Jan 3:S1473-3099(23)00813.
    PubMed: https://www.amedeo.com/p2.php?id=38184005&s=cov&pm=2
     
    Share: https://m.amedeo.com/38184005
36. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al.
    TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
    Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
    PubMed: https://www.amedeo.com/p2.php?id=38211737&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38211737
37. GARCIA-RODRIGUEZ I, Moreni G, Capendale PE, Mulder L, et al.
    Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.
    Antiviral Res. 2024 Jan 6:105798. doi: 10.1016/j.antiviral.2024.105798.
    PubMed: https://www.amedeo.com/p2.php?id=38190972&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38190972

https://etidioh.wordpress.com/2024/01/14/coronavirus-disease-research-references-by-amedeo-january-14-24/

1. NGO B, Rendell MS.
   Major Update: Masks for Prevention of SARS-CoV-2 in Health Care and Community
   Settings.
   Ann Intern Med. 2023;176:eL230358.
   PubMed: https://www.amedeo.com/p2.php?id=38109756&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109756
2. BROWN TS, Mohareb AM, LaRocque RC.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230347.
   PubMed: https://www.amedeo.com/p2.php?id=38109751&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109751
3. REZNICK SE.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230346.
   PubMed: https://www.amedeo.com/p2.php?id=38109749&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109749
4. JIRMANUS LZ, Schwartzmann EG, Davids JD, Gullette MM, et al.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230350.
   PubMed: https://www.amedeo.com/p2.php?id=38109748&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109748
5. SHENOY ES, Doron S, Branch-Elliman W.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230351.
   PubMed: https://www.amedeo.com/p2.php?id=38109747&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109747
6. GAFFNEY A, Himmelstein DU, Woolhandler S.
   Asthma Disparities in the United States Narrowed During the COVID-19 Pandemic:
   Findings From a National Survey, 2019 to 2022.
   Ann Intern Med. 2023 Dec 19. doi: 10.7326/M23-2100.
   PubMed: https://www.amedeo.com/p2.php?id=38109736&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109736
7. LOOI MK.
   Covid-19: WHO adds JN.1 as new variant of interest.
   BMJ. 2023;383:p2975.
   PubMed: https://www.amedeo.com/p2.php?id=38128957&s=cov&pm=2
    
   Share: https://m.amedeo.com/38128957
8. ALTMANN DM, Pagel C.
   Long covid: where are we, what does it say about our pandemic response, and where
   next?
   BMJ. 2023;383:p2972.
   PubMed: https://www.amedeo.com/p2.php?id=38114255&s=cov&pm=2
    
   Share: https://m.amedeo.com/38114255
9. IACOBUCCI G.
   Flu and covid levels rise in England.
   BMJ. 2023;383:p2965.
   PubMed: https://www.amedeo.com/p2.php?id=38114251&s=cov&pm=2
    
   Share: https://m.amedeo.com/38114251
10. IACOBUCCI G.
    Covid-19: Bereaved families group collects BMJ award for holding ministers to
    account.
    BMJ. 2023;383:2955.
    PubMed: https://www.amedeo.com/p2.php?id=38101907&s=cov&pm=2
     
    Share: https://m.amedeo.com/38101907
11. BALABAN N, Mohyuddin GR, Kashi A, Massarweh A, et al.
    Projecting complete redaction of clinical trial protocols (RAPTURE): redacted
    cross sectional study.
    BMJ. 2023;383:e077329.
    PubMed: https://www.amedeo.com/p2.php?id=38097263&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38097263
12. IACOBUCCI G.
    Covid inquiry: What did Johnson say about underestimated risks, excess deaths,
    and his missing WhatsApps?
    BMJ. 2023;383:2914.
    PubMed: https://www.amedeo.com/p2.php?id=38081644&s=cov&pm=2
     
    Share: https://m.amedeo.com/38081644
13. LIU W, Gong F, Zheng X, Pei L, et al.
    Factors associated with prolonged viral shedding of SARS-CoV-2 Omicron variant
    infection in Shanghai: A multicenter, retrospective, observational study.
    J Med Virol. 2023;95:e29342.
    PubMed: https://www.amedeo.com/p2.php?id=38130170&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38130170
14. LEE DH, Han E, Ryu S, Choi HJ, et al.
    Clinical performance of the STANDARD M10 SARS-CoV-2 rapid RT-PCR assay in
    patients visiting an emergency department.
    J Med Virol. 2023;95:e29330.
    PubMed: https://www.amedeo.com/p2.php?id=38117224&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38117224
15. KAPUSTA J, Babicki M, Pieniawska-Smiech K, Kaluzinska-Kolat Z, et al.
    Clinical and electrocardiographic correlates of myocardial dysfunction after
    COVID-19 in nonhospitalised patients in long-term follow-up. Data from the polish
    long-covid cardiovascular study.
    J Med Virol. 2023;95:e29331.
    PubMed: https://www.amedeo.com/p2.php?id=38112151&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38112151
16. ZHOU Y, Liu Y, Jiang L, Zhang R, et al.
    Azvudine and nirmatrelvir-ritonavir in hospitalized patients with
    moderate-to-severe COVID-19: Emulation of a randomized target trial.
    J Med Virol. 2023;95:e29318.
    PubMed: https://www.amedeo.com/p2.php?id=38112106&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38112106
17. SULLIVAN DJ, Focosi D, Hanley DF, Cruciani M, et al.
    Outpatient randomized controlled trials to reduce COVID-19 hospitalization:
    Systematic review and meta-analysis.
    J Med Virol. 2023;95:e29310.
    PubMed: https://www.amedeo.com/p2.php?id=38105461&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38105461
18. LI Y, Yamamoto S, Horii K, Mizoue T, et al.
    Long COVID during the Omicron predominant waves among Japanese healthcare
    workers.
    J Med Virol. 2023;95:e29322.
    PubMed: https://www.amedeo.com/p2.php?id=38103017&s=cov&pm=2
     
    Share: https://m.amedeo.com/38103017
19. FEGHOUL L, Caillault A, Peyrony O, Salmona M, et al.
    Respiratory torque teno virus load at emergency department visit predicts
    intensive care unit admission of SARS-CoV-2 infected patients.
    J Med Virol. 2023;95:e29319.
    PubMed: https://www.amedeo.com/p2.php?id=38102899&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38102899
20. ALLEL K, Cabada MM, Lau C, Mills D, et al.
    Causes of death among international travellers in Peru, 2017 to 2021.
    J Travel Med. 2023 Dec 21:taad163. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38127642&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127642
21. GAO Q, Weng Z, Feng Y, Gong T, et al.
    KPNA2 suppresses porcine epidemic diarrhea virus replication by targeting and
    degrading virus envelope protein through selective autophagy.
    J Virol. 2023;97:e0011523.
    PubMed: https://www.amedeo.com/p2.php?id=38038431&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38038431
22. HARRIS E.
    Using Throat Swabs Improved Sensitivity in Detecting SARS-CoV-2.
    JAMA. 2023 Dec 20. doi: 10.1001/jama.2023.25267.
    PubMed: https://www.amedeo.com/p2.php?id=38117510&s=cov&pm=2
     
    Share: https://m.amedeo.com/38117510
23. HARRIS E.
    Program Offering Free COVID-19 and Flu Services Expands Nationwide.
    JAMA. 2023 Dec 20. doi: 10.1001/jama.2023.25268.
    PubMed: https://www.amedeo.com/p2.php?id=38117506&s=cov&pm=2
     
    Share: https://m.amedeo.com/38117506
24. CHARLIER P.
    Death and end of life in France after COVID-19.
    Lancet. 2023;402:2290.
    PubMed: https://www.amedeo.com/p2.php?id=38103938&s=cov&pm=2
     
    Share: https://m.amedeo.com/38103938
25. HORTON R.
    Offline: Boris Johnson and COVID-19-more light than heat.
    Lancet. 2023;402:2277.
    PubMed: https://www.amedeo.com/p2.php?id=38103935&s=cov&pm=2
     
    Share: https://m.amedeo.com/38103935
26. BLACK CL, Kriss JL, Razzaghi H, Patel SA, et al.
    Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage
    Among Adults – United States, Fall 2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1377-1382.
    PubMed: https://www.amedeo.com/p2.php?id=38127675&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127675
27. HARRINGTON PR, Cong J, Troy SB, Rawson JMO, et al.
    Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in
    Randomized, Double-Blind, Placebo-Controlled Trials – United States and
    International Sites, 2021-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1365-1370.
    PubMed: https://www.amedeo.com/p2.php?id=38127674&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127674
28. RESES HE, Dubendris H, Haas L, Barbre K, et al.
    Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19
    Vaccines Among Nursing Home Residents – National Healthcare Safety Network,
    United States, December 2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1371-1376.
    PubMed: https://www.amedeo.com/p2.php?id=38127673&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127673
29. SMITH DJ, Lambrou A, Patel P.
    SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.
    MMWR Morb Mortal Wkly Rep. 2023;72:1357-1364.
    PubMed: https://www.amedeo.com/p2.php?id=38127665&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127665
30. Covid Update: ITT Episode 23.
    N Engl J Med. 2023;389:e52.
    PubMed: https://www.amedeo.com/p2.php?id=38118021&s=cov&pm=2
     
    Share: https://m.amedeo.com/38118021
31. BENZLER J.
    Contact-tracing app predicts risk of SARS-CoV-2 transmission.
    Nature. 2023 Dec 21. doi: 10.1038/d41586-023-04063.
    PubMed: https://www.amedeo.com/p2.php?id=38129614&s=cov&pm=2
     
    Share: https://m.amedeo.com/38129614
32. FERRETTI L, Wymant C, Petrie J, Tsallis D, et al.
    Digital measurement of SARS-CoV-2 transmission risk from 7 million contacts.
    Nature. 2023 Dec 20. doi: 10.1038/s41586-023-06952.
    PubMed: https://www.amedeo.com/p2.php?id=38122820&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38122820
33. HALL S.
    Vaccines reduce the risk of long COVID in children.
    Nature. 2023 Dec 20. doi: 10.1038/d41586-023-04032.
    PubMed: https://www.amedeo.com/p2.php?id=38114835&s=cov&pm=2
     
    Share: https://m.amedeo.com/38114835
34. SUTHAR PP, Hughes K, Mafraji M, Akyuz M, et al.
    Case 324.
    Radiology. 2023;309:e222747.
    PubMed: https://www.amedeo.com/p2.php?id=38112552&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38112552
35. ABEGAZ FA, Dos Santos PT, Mogeni OD, Guarnacci T, et al.
    Evaluating Quality Management and Diagnostics Microbiology Performance Within an
    International External Quality Assessment (EQA) Program Serving National One
    Health Sector Reference Laboratories Across Asia: Experience Amid the Coronavirus
    Disease 2019 (COVID-19) Pandemic.
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38118017&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118017
36. KWON SY, Gautam S, Poudel K, Banneheke H, et al.
    Utility and Evaluation of Applied Project Management Processes Within a Large
    Multicountry Health Systems Development Project Conducted During the Coronavirus
    Disease 2019 (COVID-19) Pandemic.
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38118010&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118010
37. MUSTAFA T, Niazi MRK, Lakdawala Z, Mirza S, et al.
    Regional and National Trends in Consumption of Antimicrobials in Pakistan; Pre
    and Post-COVID (2019-2021).
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38118009&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118009
38. LESLIE T, Parry C, Ondoa P, Walsh T, et al.
    The Reality of Antimicrobial Resistance and Antibiotic Usage Data in Asia: The
    CAPTURA Experience.
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38118008&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118008
39. HAYDEN MK, Hanson KE, Englund JA, Lee MJ, et al.
    The Infectious Diseases Society of America Guidelines on the Diagnosis of
    Coronavirus Disease 2019 (COVID-19): Molecular Diagnostic Testing.
    Clin Infect Dis. 2023 Dec 19:ciad646. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38112284&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38112284
40. SMITH TC.
    Long COVID: Alice Evans, Brucellosis, and Reflections on Infectious Causes of
    Chronic Disease.
    Clin Infect Dis. 2023;77:1644-1647.
    PubMed: https://www.amedeo.com/p2.php?id=37462272&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37462272
41. MONTGOMERY MP, Morris SE, Rolfes MA, Kittikraisak W, et al.
    The role of asymptomatic infections in influenza transmission: what do we really
    know.
    Lancet Infect Dis. 2023 Dec 18:S1473-3099(23)00619.
    PubMed: https://www.amedeo.com/p2.php?id=38128563&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38128563
42. YANG S, Yu Y, Xu Y, Jian F, et al.
    Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.
    Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00744.
    PubMed: https://www.amedeo.com/p2.php?id=38109919&s=cov&pm=2
     
    Share: https://m.amedeo.com/38109919
43. GANDHI M.
    Post-viral sequelae of COVID-19 and influenza.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00762.
    PubMed: https://www.amedeo.com/p2.php?id=38104584&s=cov&pm=2
     
    Share: https://m.amedeo.com/38104584
44. XIE Y, Choi T, Al-Aly Z.
    Long-term outcomes following hospital admission for COVID-19 versus seasonal
    influenza: a cohort study.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684.
    PubMed: https://www.amedeo.com/p2.php?id=38104583&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38104583
45. WANG S, Wang Z, Li Y, Tu S, et al.
    Generation of whole-porcine neutralizing antibodies of an alphacoronavirus by
    single B cell antibody technology.
    Antiviral Res. 2023;220:105754.
    PubMed: https://www.amedeo.com/p2.php?id=37967753&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37967753

https://etidioh.wordpress.com/2023/12/25/coronavirus-disease-research-references-by-amedeo-december-25-23/